Having acquired the Applied Biosystem
agency business from LabIndia Instruments, Invitrogen has better access
to a robust line of products
|Revenue 180 crore*
|MD: Mr Devashish Ohri
|Business: Manufacturer and
supplier of biotech consumables and instruments
|Start-up Year: 2005
|Address: First Technology Place, 3
Bangalore - 560066
Life Technologies Corporation, headquartered
in California, US, operates in India as Invitrogen Bioservices India,
specializing in biotech consumables and benchtop instruments.
Invitrogen India commenced operations in 2005 from Bangalore. Having
acquired the Applied Biosystems agency business from LabIndia
Instruments, Invitrogen has better access to a robust line of products
that provide end-to-end solutions, as well as customer and technical
Invitrogen BioServices offers its products and solutions through three
key functional divisions: Co-located state-of-the-art facility housing
commercial, research and support functions, technology driven R&D
and manufacturing operations, and global customer service division.
According to BioSpectrum estimates, company has clocked life sciences
sales revenue of
180 crore in 2010-11 as against
140 crore in 2009-10
from its India operations.
In September 2010, Life Technologies signed cell line license
agreements with a number of companies from across the world including
Indian Immunologicals of Hyderabad to provide rights to its proprietary
CHO (Chinese hamster ovary) cell lines for the production of
recombinant proteins used as therapeutic agents and vaccines.
In August 2010, Life Technologies launched its Applied Biosystems 3500
Dx Series Genetic Analyzers, the first CE IVD-marked capillary
electrophoresis system for nucleic acid analysis, across Asia Pacific
Mr Devashish Ohri, managing director, Life Technologies South Asia
says, “Invitrogen consumables along with Applied Biosystems instruments
provide a wide spectrum of solutions to meet customer needs and align
with their growth strategy.
The next wave of growth will now come in applied markets relating to
biofuels, diagnostics, forensics, agriculture, which according to ABLE
could be 25 percent of the total biotech market size.”